Tilray Medical Expands Australia Portfolio With New Marijuana Flower, Vapes, Extracts and Pastilles
- Tilray Medical is launching its largest expansion in Australia, introducing a wider range of medical marijuana products including flower, extracts, vapes, and pastilles under its Redecan and Good Supply brands.
- The expansion aims to broaden treatment options for patients and healthcare professionals and meet the growing demand in Australia’s regulated medical marijuana market.
- The move aligns with Tilray’s long-term strategy in Australia, leveraging its experience in prescriber, pharmacy, and clinical distribution channels to deepen its market presence.
- Tilray, operating in 20 countries, emphasizes its commitment to global growth by providing quality cannabis products and increasing access through compliant channels across multiple continents.
Tilray Medical announced Thursday that it is rolling out its largest expansion in Australia to date, adding a wider range of medical marijuana products as it deepens its presence in one of the world’s more established regulated cannabis markets. According to the company, the expanded lineup will be introduced over the coming months and will include products sold under its Redecan and Good Supply brands. The new offerings are set to span multiple categories, including marijuana flower, extracts, vapes and pastilles. Tilray said the move is intended to broaden treatment options for both patients and healthcare professionals while helping meet rising demand within Australia’s medical marijuana system.
The company said Redecan’s additions will cover several product formats, while Good Supply will focus on new flower products. Tilray described the expansion as part of its long-term strategy in Australia, where it has operated for several years through prescriber, pharmacy and clinical distribution channels.
Rajnish Ohri, President, International, Tilray Brands, stated, “Australia represents an important strategic market within our international growth strategy. This launch reflects our long-term commitment to delivering quality, differentiated cannabis products.”
Mr. Ohri continued, “By bringing together proven genetics, rigorous quality standards, and our strong local market expertise, we are excited to support the evolving needs of the Australian community. This milestone reflects our continued investment across priority global markets, as we broaden access to trusted cannabis products worldwide.”
Tilray said it currently supplies medical marijuana in 20 countries across five continents. The company, which traces its roots to Canada’s early medical marijuana industry, said it remains focused on expanding access to regulated products through compliant distribution channels in markets across Europe, North America and Australia.
The latest move gives Tilray a broader footprint in Australia at a time when international marijuana companies continue looking to strengthen their position in overseas medical markets.